Entera Bio announces acceptance of EB613 abstracts for WCO-IOF-ESCEO

Entera Bio (ENTX) announced that the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases Scientific Programme Committee has accepted both submitted abstracts related to EB613 for presentation at the WCO-IOF-ESCEO congress. The congress will take place at the Roma Convention Center, Rome, Italy from April 10 to April 13, 2025. EB613 is being developed as the first once-daily oral anabolic PTH(1-34) tablet treatment to support earlier osteoanabolic intervention, for high-risk post-menopausal women with osteoporosis. In a Placebo-controlled Phase 2 study, 6 months of EB613 treatment demonstrated fast onset of action and robust increases in BMD at all skeletal sites. Further, EB613 induced increases in bone formation and suppression of bone resorption. “EFFECTS OF EB613 TABLETS ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY” will be presented as an Oral Presentation Friday April 11 at 10:00 GMT in the Auditorium A. “EB613 TABLET TREATMENT – DOES PK DRIVE BONE MODELING VERSUS BONE REMODELING?” will be presented as a Poster Presentation Friday April 11th – Sunday April 13th 2025.